Online and face-to-face programmes to suit your CPD needs, apply now for September 2018
Page URL: https://www.bionews.org.uk/page_91818

US company's stem cell trial put on hold

23 August 2009
Appeared in BioNews 522

The US Food and Drug Administration (FDA) has delayed the start of a clinical trial that plans to use human embryonic stem cells (ES cells)  to treat spinal cord injury. The trial is being run by Californian based company Geron. The FDA originally gave the go-ahead for the trial in January, but now has halted the start in order to review new data submitted by Geron.

The company has created oligodendrocyte precursors from human ES cells. Oligodendrocytes support nerve cells and Geron hopes the cell therapy, called GRNOPC1, can promote healing in people with recently severed spinal cords. Geron has been testing GRNOPC1 on animals, studying its effect in increasing doses and in other neurological diseases. The FDA has put the trial on hold while it reviews the new animal data.

There has been speculation as to what the halt means. It could be that the new data has raised concerns about the safety of the product. A particular concern with any stem cell therapy is that the cells could grow uncontrollably, giving rise to tumours. Alternatively, the FDA may just need more time to consider the new data.

The halting of clinical trials is not unusual, especially with such new or innovative treatments. Stem cells offer exciting promise for future therapies, but there are many significant technical hurdles to overcome before they will be seen in clinics. Many researchers believe that ES cells have the potential to be developed into new treatments for cancer, neurological diseases, diabetes and more. Some religious and pro-life groups contest the use of ES cells, but research that seeks new treatments for currently incurable diseases continues.

SOURCES & REFERENCES
FDA Delays Geron's Human Embryonic Stem Cell Research Trials, Seeks Data
Life News |  19 August 2009
First embryonic stem-cell trial placed on hold by FDA
Nature Blogs |  19 August 2009
Geron: FDA delays 1st trial of stem cell treatment
Forbes.com |  18 August 2009
Human tests of Geron's spinal-cord medication put on hold
Mercury News |  18 August 2009
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
21 March 2011 - by MacKenna Roberts 
A US company has launched an experimental neural stem cell clinical trial for patients paralysed by spinal injury. StemCells Inc will extract neural stem cells from donated aborted fetuses to be injected into the spines of patients with chest-level spinal cord injury...
18 October 2010 - by Dr Lux Fatimathas 
A patient paralysed through spinal cord injury has become the first person to receive human embryonic stem (ES) cell treatment in a clinical trial being conducted in the United States...
27 September 2010 - by Matthew Smart 
Scientists from Cancer Research UK, Cambridge have suggested a new model for gut stem cell renewal. It was thought that gut stem cells could only renew themselves via a process of hierarchical cell division...
23 November 2009 - by Alison Cranage 
Stem cell therapy came one step closer to being tested for the first time in people this week, as a US company applied to the Food and Drug Administration (FDA) for a licence to start a clinical trial. The embryonic stem (ES) cell therapy is being developed to treat Stargardt, a currently incurable disease that causes blindness in young people....
8 November 2009 - by Dr Jay Stone 
American company Geron Corporation (GC) has been given permission to resume its clinical trials testing the embryonic stem cell treatment GRNPOC1....
28 September 2009 - by Dr Marianne Kennedy 
The US Food and Drug Administration (FDA) has granted approval to NeuralStem Inc., a Maryland-based biotherapeutics company, to conduct the first human trial using neural stem cells for treatment of amyotrophic lateral sclerosis (ALS). ALS is a type of motor neuron disease often referred to as 'Lou Gehrig's' and 'Maladie de Charcot'. The late-onset condition, of unknown cause, affects approximately two in 100,000 people, including the UK physicist Stephen Hawking and US rock gui...
6 September 2009 - by Nishat Hyder 
Information has come to light regarding the US Food and Drug Adminstration (FDA)'s freeze on the clinical trails of GRNOPC1, a groundbreaking therapy for spinal cord injury derived from human embryonic stem cells (ES cells) being undertaken by biotech company Geron...
26 January 2009 - by Antony Blackburn-Starza 
The US Food and Drug Administration (FDA) has allowed the biotech firm, Geron, to begin clinical trials using embryonic stem (ES) cells to help treat spinal cord injury sufferers who have become paralysed from the chest down. The product known as GRNOPC1 will be tested for its...
1 December 2008 - by Katy Sinclair 
The annual conference of the Progress Educational Trust - 'Is the embryo sacrosanct? Multi-faith perspectives' - was expertly chaired by Baroness Haleh Afshar, Founder and Chair of the Muslim Women's Network and Visiting Professor of Islamic Law at the University of Strasbourg. The panel comprised Anil Bhanot, General Secretary of the Hindu...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.